Glukem Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -7459.00%
- Ebitda -93.72%
- Net Worth -4.00%
- Total Assets -2.06%
About Glukem Pharmaceuticals
Glukem Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 February 2009 and has a history of 15 years and 11 months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233TG2009PTC062750
-
Company No.
062750
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Feb 2009
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Glukem Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramanaiah Madupaduga
|
Managing Director | 05-Feb-2015 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Hazra Kumar
|
Director | 01-Aug-2015 | Current |
|
Rakesh Chinnala
|
Director | 01-Aug-2015 | Current |
|
Varun Madupaduga
|
Director | 05-Feb-2015 | Current |
|
Rami Kolli
|
Director | 01-Aug-2015 | Current |
|
Omkar Bommu
|
Director | 01-Aug-2015 | Current |
Financial Performance of Glukem Pharmaceuticals.
Glukem Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 7459% decrease in profit. The company's net worth dipped by a decrease of 4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glukem Pharmaceuticals?
In 2023, Glukem Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Valvum Pro Sciences Private LimitedOmkar Bommu is a mutual person
-
Glukem Biocare Private LimitedHazra Kumar, Ramanaiah Madupaduga and 4 more are mutual person
-
Voyage Pharma Private LimitedHazra Kumar and Rakesh Chinnala are mutual person
-
Vidur Human Care Private Limited
Ramanaiah Madupaduga and Varun Madupaduga are mutual person
-
Tryko Homes Private Limited
Rakesh Chinnala is a mutual person
-
Lorven Infraacon Llp
Varun Madupaduga is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Glukem Pharmaceuticals?
Unlock and access historical data on people associated with Glukem Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glukem Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glukem Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
